Literature DB >> 22454952

The influence of urinary pH on the elimination of mexiletine.

M A Kiddie1, C M Kaye, P Turner, T R Shaw.   

Abstract

1 The plasma elimination half-life of mexiletine was measured in four subjects when the urine was rendered (a) acidic and (b) alkaline. 2 Urinary acidification (pH 5.0) was associated with a plasma elimination half-life of 2.8 h and 57.5% of the intravenous dose was excreted in the urine within 48 hours. When the urine was alkaline (pH 8.0) the half-life increased to 8.6 h with negligible amounts of drug appearing in the urine. 3 Urinary pH varies widely in cardiac patients and should be controlled or monitored to provide better therapeutic precision with mexiletine.

Entities:  

Year:  1974        PMID: 22454952      PMCID: PMC1402565          DOI: 10.1111/j.1365-2125.1974.tb00241.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

Review 1.  RENAL TUBULAR MECHANISMS FOR EXCRETION OF ORGANIC ACIDS AND BASES.

Authors:  I M WEINER; G H MUDGE
Journal:  Am J Med       Date:  1964-05       Impact factor: 4.965

2.  INFLUENCE OF URINARY PH ON EXCRETION OF AMPHETAMINE.

Authors:  A H BECKETT; M ROWLAND; P TURNER
Journal:  Lancet       Date:  1965-02-06       Impact factor: 79.321

3.  A study of the inverse relationship between pKa and rate of renal excretion of phenylbutazone analogs in man and dog.

Authors:  A B GUTMAN; P G DAYTON; T F YU; L BERGER; W CHEN; L E SICAM; J J BURNS
Journal:  Am J Med       Date:  1960-12       Impact factor: 4.965

4.  Urinary pH.

Authors:  J S ELLIOT; R F SHARP; L LEWIS
Journal:  J Urol       Date:  1959-02       Impact factor: 7.450

5.  Studies in diurnal variation of water and electrolyte excretion; nocturnal diuresis of water and sodium in congestive cardiac failure and cirrhosis of the liver.

Authors:  R GOLDMAN
Journal:  J Clin Invest       Date:  1951-11       Impact factor: 14.808

6.  The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide.

Authors:  J D Allen; J M Kofi; R G Shanks; S A Zaidi
Journal:  Br J Pharmacol       Date:  1970-05       Impact factor: 8.739

7.  Preliminary studies on the pharmacology of an antidysrhythmic, Kö 1173, in man.

Authors:  M A Kiddie; R B Royds; T R Shaw
Journal:  Br J Pharmacol       Date:  1973-03       Impact factor: 8.739

8.  Proceedings: The influence of urine pH on the renal excretion of practolol and propranolol.

Authors:  C M Kaye; D G Robinson; P Turner
Journal:  Br J Pharmacol       Date:  1973-09       Impact factor: 8.739

9.  Drug therapy. Serum drug concentrations as therapeutic guides.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1972-08-03       Impact factor: 91.245

10.  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Authors:  N P Campbell; J G Kelly; R G Shanks; N C Chaturvedi; J E Strong; J F Pantridge
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

  10 in total
  10 in total

1.  [Treatment with mexiletine. Clinical and pharmacokinetic studies].

Authors:  H Breithaupt; A Schmidt
Journal:  Klin Wochenschr       Date:  1988-06-01

Review 2.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 3.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 4.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

5.  Effect of rifampicin treatment on the kinetics of mexiletine.

Authors:  P J Pentikäinen; I H Koivula; H A Hiltunen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 6.  Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.

Authors:  C Y Chew; J Collett; B N Singh
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

7.  Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.

Authors:  P Lledó; S M Abrams; A Johnston; M Patel; R M Pearson; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Mechanistic PBPK Modeling of Urine pH Effect on Renal and Systemic Disposition of Methamphetamine and Amphetamine.

Authors:  Weize Huang; Lindsay C Czuba; Nina Isoherranen
Journal:  J Pharmacol Exp Ther       Date:  2020-03-20       Impact factor: 4.030

9.  Cirrhosis of the liver markedly impairs the elimination of mexiletine.

Authors:  P J Pentikäinen; S Hietakorpi; M O Halinen; L M Lampinen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

10.  Identifying organic chemicals not subject to bioaccumulation in air-breathing organisms using predicted partitioning and biotransformation properties.

Authors:  Frank Wania; Ying Duan Lei; Sivani Baskaran; Alessandro Sangion
Journal:  Integr Environ Assess Manag       Date:  2021-12-16       Impact factor: 3.084

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.